(Click on the image to see the movie)
Cell Receptor has identified a group of quite well tolerated compounds with the remarkable ability to prevent growing benign and malignant cells from taking up growth factors. The target here is a part of a mechanism we have discovered that has not yet received therapeutic attention.
The project was born in the cell culture laboratory and is now in the translational phase, with the goal of clinical application.
90% of cancer-related deaths are caused by metastases. The new therapy has the potential to prevent the seeding of metastases from malignant tumors. Also, we expect it to enable curbing pathological immune responses of autoimmune diseases, as autoimmunity is associated with proliferation of cells in the immune system.
The project has now reached a stage where proof of concept will be provided through a clinical trial. The type IIa trial is intended to address the prevention of metastases and is to be conducted by a reputable oncology organization. The study will be unusually low cost. Cell Receptor will fund the study and is currently seeking venture capital for this purpose and welcomes appropriate scientific and financial partnerships.
Are you interested in our project? Then please contact us.